Pfizer names its head of oncology

Pfizer names oncology chief and company veteran Boshoff as chief scientific officer
Pfizer Inc. named oncology chief Chris Boshoff as its new chief scientific officer on Wednesday, replacing Mikael Dolsten starting Jan. 1. The drug company had been searching for a new chief scientific officer since July with Dolsten leaving after 15 years at the company,
Pfizer Taps Cancer Chief to Lead Research, Find Hit Drugs
Pfizer Inc. named oncology research head Chris Boshoff as the drug company’s chief scientific officer, replacing Mikael Dolsten, whose planned departure was announced earlier this year.
Doubling down on its strategy, Pfizer names its head of oncology as new research chief
Pfizer, despite pressure from investors to look outside, elevates its cancer chief Chris Boshoff to lead overall R&D.
Amgen Names Howard Chang as Chief Scientific Officer
Amgen on Wednesday said Howard Chang will join the company as senior vice president of research, effective Dec. 16. The company said Chang, who will also serve as chief scientific officer, will establish and lead research priorities within its rare disease, oncology, inflammation and cardiometabolic therapeutic areas.
Pfizer confirms Chris Boshoff as chief scientific officer
Pfizer (PFE) announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD,
Pfizer, under pressure to change, names oncology head as new R&D chief
Chris Boshoff will replace Mikael Dolsten, who’s stepping down after 15 years leading research at the drugmaker.
Pfizer Announces New Chief Scientific Officer and President, Research & Development
Pfizer Inc. (NYSE: PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer and President,
Pfizer Names Chris Boshoff Chief Scientific Officer And President, R&D, Effective Jan.1
Drug major Pfizer Inc. (PFE) announced Wednesday the appointment of Chris Boshoff as Chief Scientific Officer and President, Research
Pfizer names oncology head Chris Boshoff as R&D chief
Pfizer said on Wednesday it has named company veteran and oncology head Chris Boshoff as its chief of research and development. The appointment comes at a time when Pfizer is facing criticism from activist investor Starboard for overspending on big acquisitions and failing to produce profitable new drugs from those deals or its internal research and development.
Pfizer Names New R&D Chief
Company veteran Chris Boshoff, who has led Pfizer’s cancer research and marketing for more than a year, will become chief scientific officer starting Jan. 1.
BioSpace4d
Pfizer Shakes Up C-Suite, Elevating Cancer Chief Boshoff to CSO
Chris Boshoff will take over as Pfizer’s next chief scientific officer as of January 1, replacing Mikael Dolsten who led the ...
STAT4d
Investors tell Silence Therapeutics to shush
Silence Therapeutics presented what seemed like positive data on zerlasiran, its experimental drug for reducing ...
ENDPOINTS NEWS4d
Pfiz­er taps on­col­o­gy head Boshoff as Dol­sten's chief sci­en­tif­ic of­fi­cer suc­ces­sor
Chris Boshoff will become Pfizer's chief scientific officer and R&D president on January 1, replacing Mikael Dolsten. Roger ...
Pfizer promotes oncology chief to lead R&D as activist Starboard circles
Bourla said in a statement that Boshoff was “the ideal leader to propel Pfizer’s R&D engine forward and transform it into a world-leading organisation with a more focused strategy, driving the ...